

1 Supplementary Methods

2 Patient Selection

3 Spatial transcriptomic (CosMx term) profiling was undertaken on FFPE fixed resection
4 specimens post-neoadjuvant therapy and matched pre-treatment biopsies from 5
5 patients who had undergone neoadjuvant FLOT based chemotherapy for
6 oesophageal/GOJ adenocarcinoma in the prior 2 years followed by curative
7 oesophagectomy. All patients selected had experienced a partial response to therapy
8 (TRG3) as defined by an NHS pathologist expert in gastro-oesophageal cancer. TRG3 was
9 selected to provide the balance between areas of response and residual disease and
10 allow investigation of mechanisms of treatment resistance and recurrence, including
11 areas of minimally residual disease in fibrosis.

12

13 Computational analysis

14

15 *Integrated single-cell RNA-seq reference*

16 Reciprocal principal component analysis (RPCA) was used to integrate three published
17 oesophageal adenocarcinoma (OAC) single-cell or single-nucleus RNA-seq datasets
18 using Seurat v5.2.0. The datasets comprised 10x Genomics single-cell RNA-seq, Drop-
19 seq single-cell RNA-seq, and single-nucleus RNA-seq/multiome. RPCA integration was
20 used for cross-study co-embedding, harmonisation of cell-type annotations, and
21 construction of a reference atlas.

22 Pre-processed, post-QC expression matrices and metadata were obtained from the
23 original studies. Because the datasets were generated using different capture platforms
24 and tissue-processing workflows, study-specific QC procedures were retained rather
25 than applying a single uniform QC threshold across all datasets. These published QC
26 pipelines included platform-appropriate filtering of low-complexity cells or nuclei, high
27 mitochondrial-content barcodes, predicted doublets or empty droplets where
28 applicable, and sample or library-quality metrics. In the 10x Genomics single-cell RNA-
29 seq dataset, reported QC included processing of samples with high cell viability, filtering

30 of cells with low or excessively high detected gene counts, removal of cells with high
31 mitochondrial RNA content, and exclusion of predicted doublets. In the single-
32 nucleus/multiome dataset, published processing included filtering of low-complexity
33 nuclei, high mitochondrial-content barcodes, ambient RNA correction, and doublet
34 detection. For the Drop-seq dataset, post-QC cells from the published analysis were
35 retained.

36 Where applicable, datasets were subset to retain primary oesophageal tumour and
37 normal tissue-derived cells, with metastatic samples excluded. Metadata variables,
38 including tissue source, treatment status, donor, sample, and study of origin, were
39 harmonised across datasets. Cell-type annotations were standardised into nine broad
40 lineages: normal epithelium, malignant epithelium, endothelial cells, fibroblasts, and
41 five immune-cell lineages.

42 Each broad lineage was subsequently analysed independently. Within each lineage,
43 cells underwent normalisation, principal component analysis, nearest-neighbour graph
44 construction, clustering, and UMAP visualisation following the recommended Seurat
45 workflow. Fine-level cell-type identities were assigned using Azimuth and SingleR,
46 supplemented by manual curation based on established marker-gene expression, prior
47 biological knowledge, and published literature. Azimuth mapping to the human PBMC
48 reference was used to support immune-cell annotation and was not used to assign
49 epithelial, malignant, endothelial, or fibroblast identities.

50

51 *Pre-processing and quality control of CosMx spatial transcriptomics data*

52 CosMx spatial transcriptomics data were analysed independently for each slide to
53 minimise potential slide-specific batch effects. The dataset comprised five biopsy
54 samples on one slide and five resection samples distributed across three slides. Pre-
55 processing and quality control were performed following Bruker's recommended
56 workflow described in the "Basics of CosMx Analysis in R" vignette.

57 Unique cell identifiers were generated using the prefix "c" followed by slide number, field
58 of view, and cell number, for example c_1_23_452. These identifiers were applied
59 consistently across the raw count matrix, metadata, polygon files, and field-of-view
60 position files.

61 Negative control probes and system control probes were extracted from the raw count
62 matrix and saved separately for downstream use, including supervised InSituType
63 annotation. Cells containing fewer than 50 detected transcripts were removed to
64 exclude low-complexity cells. Cells with a surface area greater than 30,000 μm^2 were
65 also excluded to reduce the inclusion of likely mis-segmented, merged, or otherwise
66 artefactual cells.

67 A Seurat object was created from the raw count matrix and associated metadata and cell
68 centroid coordinates were extracted from the metadata and used to construct a
69 centroid-based spatial feature layer. Coordinates were converted into a spatial field-of-
70 view object, which was added to the Seurat object as the global spatial layer.

71

72 *Cell-type annotation and consensus label generation for CosMx data*

73 To generate robust and reproducible cell-type annotations for the OAC CosMx dataset,
74 multiple independent annotation frameworks were applied. Their outputs were
75 harmonised and combined into a consensus cell-type label. This approach was used to
76 reduce dependence on any single classifier and to integrate complementary evidence
77 from spatial-platform-aware models, reference mapping, marker-gene classifiers, and
78 correlation-based annotation.

79

80 *Individual annotation methods*

81 Five annotation approaches were used.

82 **InSituType** was run in supervised mode using a pseudo-bulk reference derived from the
83 integrated scRNA-seq reference. A reference gene-expression matrix was constructed
84 from the scRNA-seq dataset using genes shared with the CosMx 6,000-plex panel. For
85 each annotated reference cell type, the top differentially expressed genes were
86 identified, and the subset overlapping the CosMx panel was retained. These genes were
87 used to generate pseudo-bulk profiles representing each reference cell type. InSituType
88 was then run using the raw CosMx counts together with the negative control count
89 matrix. InSituType was treated as the primary spatial-platform-aware classifier because
90 it is designed for in situ transcriptomic data, but its predictions were evaluated in
91 combination with independent classifiers, marker expression, and manual review.

92 **Latent transfer** was performed using Seurat’s anchor-based label transfer framework.
93 The pre-processed CosMx Seurat object was used as the query and the integrated
94 scRNA-seq object as the reference. Anchors were identified using 30 principal
95 components, and reference labels were transferred to CosMx cells. This approach was
96 used to capture global transcriptomic similarity between CosMx cells and the scRNA-
97 seq reference while accounting for cross-platform differences.

98 **Garnett** was used as an interpretable marker-gene-based classifier. A hierarchical
99 marker file was generated for 19 cell types known or expected to occur in OAC, using
100 established positive and negative marker-gene patterns. Garnett predictions were
101 included because marker-based classification is relatively interpretable and less
102 dependent on global cross-platform alignment, although it is constrained by marker
103 coverage and manual marker selection.

104 **Azimuth** was used for supervised reference mapping of immune populations. The
105 human PBMC Azimuth reference was used with level 1 cell-type annotations and 30
106 principal components. Azimuth predictions were used only to support immune-cell
107 annotation and were not used to classify epithelial, malignant, endothelial, or stromal
108 cells.

109 **SingleR** was used as a correlation-based annotation method. CosMx expression profiles
110 were compared with the Human Primary Cell Atlas reference provided through SingleR.
111 SingleR was included as an independent broad cell-type annotation method because it
112 performs well for abundant, transcriptionally distinct cell types.

113 Each method generated a predicted cell-type label and, where available, an associated
114 confidence, probability, or prediction score.

115

116 *Label harmonisation*

117 Because the five classifiers produced labels with different naming conventions and
118 levels of granularity, predicted labels were harmonised to a unified ontology of
119 approximately 20 biologically interpretable cell classes. These included malignant
120 epithelial cells, non-malignant epithelial cells, fibroblasts or stromal cells, endothelial
121 cells, CD4 T cells, CD8 T cells, regulatory T cells, B cells, plasma cells or plasmablasts,
122 NK cells, myeloid cells, dendritic cells, mast cells, and other or unknown cells.

123 Harmonisation was performed using string matching and regular-expression-based
124 rules, followed by manual review. Particular attention was given to ambiguous labels,
125 including plasmacytoid dendritic cells versus plasma cells, broad lymphoid labels
126 versus specific T- or B-cell annotations, and epithelial versus malignant epithelial
127 assignments.

128

129 **Weighted consensus annotation**

130 To combine predictions from the five classifiers, a weighted-voting scheme was
131 implemented. For each cell, each classifier contributed support to its predicted
132 harmonised label. The contribution of classifier i to label l was calculated as:

$$133 \quad W_{label} = \sum_i (w_i \times s_i)$$

134 where w_i is the fixed method weight and s_i is the classifier-specific confidence score. For
135 methods that did not provide a continuous confidence score, a score of 1 was assigned
136 to the predicted label and 0 to all other labels.

137 InSituType predictions were assigned the highest weight, $w = 3$, because they were
138 generated using a CosMx-aware spatial transcriptomic framework. Latent transfer and
139 Azimuth were assigned intermediate weights, $w = 2$ and $w = 1.5$, respectively,
140 reflecting their utility for reference-based mapping. SingleR was assigned $w = 1$,
141 reflecting its broad but less spatially specific correlation-based annotation. Garnett was
142 assigned $w = 0.5$ because it relies on manually curated marker sets and does not
143 provide continuous confidence scores.

144 For each cell, the label with the highest total weighted support was retained as the initial
145 consensus label. A weighted consensus confidence score was calculated as the support
146 for the winning label divided by the total support across all candidate labels. In parallel,
147 an unweighted agreement score was calculated as the proportion of classifiers assigning
148 the final consensus label. These scores were retained as measures of annotation
149 confidence.

150

151 **Manual annotation refinement**

152 Initial review with a pathologist indicated that most cells annotated as malignant
153 epithelial cells by the automated pipeline corresponded to malignant regions on

154 matched H&E images. However, some discrepancies were observed. In particular,
155 subsets of cells initially labelled as lymphoid, epithelial, other, or unknown were located
156 in regions morphologically consistent with tumour, whereas some cells initially labelled
157 as malignant epithelial cells appeared inconsistent with malignancy on H&E review.
158 To refine malignant-cell annotations, a sample-wise manual refinement procedure was
159 applied. For each sample, cells annotated as malignant epithelial, epithelial, other,
160 unknown, and any additional cell types suspected to include misclassified malignant
161 cells were subset. These cells were reprocessed using Seurat, including normalisation,
162 highly variable feature selection, scaling, PCA, nearest-neighbour graph construction,
163 clustering, and UMAP visualisation. Cluster marker genes were identified
164 using FindAllMarkers(). Marker-gene expression, spatial localisation, H&E morphology,
165 and prior biological knowledge were used to assign each cluster to a broad lineage. Cell
166 labels were revised when cluster-level evidence supported a different lineage
167 assignment from the initial consensus annotation.

168

169 *Cell-type annotation and iterative lineage refinement of CosMx data*

170 Cell-type annotation of the CosMx spatial transcriptomics dataset was performed using
171 a two-stage strategy. First, cells were assigned to broad biological lineages and
172 iteratively refined based on unsupervised clustering and marker-gene expression.
173 Second, fine cell-type annotations were generated within each broad lineage using
174 lineage-restricted supervised InSituType classification.

175

176 *Broad lineage annotation and iterative refinement*

177 CosMx cells were initially assigned to six broad biological compartments: cancer,
178 epithelial, endothelial and mural, stromal, lymphoid, and myeloid. These broad
179 compartments were selected to capture the major cellular components of OAC tissue
180 while minimising over-classification at the initial annotation stage.

181 To refine broad lineage assignments, cells from each compartment were analysed
182 iteratively. For each broad lineage, cells were subset and reprocessed independently in
183 Seurat. This included normalisation, identification of variable features, scaling, principal
184 component analysis, nearest-neighbour graph construction, clustering, and UMAP

185 visualisation. Cluster marker genes were identified using FindAllMarkers() and examined
186 to determine whether clusters were consistent with their assigned broad lineage.
187 Clusters showing marker-gene profiles inconsistent with their initial lineage assignment
188 were reassigned to the appropriate compartment. For example, clusters initially
189 assigned to lymphoid or other categories but expressing epithelial markers were moved
190 to the epithelial compartment, whereas clusters expressing canonical fibroblast,
191 endothelial, mural, myeloid, or lymphoid markers were reassigned accordingly. This
192 process was repeated iteratively until the major clusters within each broad compartment
193 showed coherent lineage-specific marker expression.
194 Broad lineage refinement was guided by canonical marker-gene expression, spatial
195 localisation, inspection of H&E morphology where available, and prior biological
196 knowledge of OAC tissue composition. The final broad lineage labels were used as the
197 basis for subsequent lineage-restricted fine annotation.

198

199 *Lineage-restricted InSituType annotation*

200 Fine cell-type annotation was performed using InSituType in supervised mode. Rather
201 than applying a single reference containing all cell types to the full CosMx dataset,
202 InSituType was run separately within each refined broad lineage. For each CosMx
203 lineage, the corresponding subset of cell types from the integrated scRNA-seq reference
204 was used to construct a lineage-matched reference. This approach reduced competition
205 between unrelated cell types and improved the biological specificity of fine annotation
206 within each compartment.

207 For each lineage-specific InSituType run, the scRNA-seq reference was subset to include
208 only cell types relevant to the corresponding CosMx broad compartment. For example,
209 CosMx stromal cells were annotated using only fibroblast reference populations,
210 including F1–F7 fibroblast states, from the scRNA-seq reference. Similarly, epithelial
211 CosMx cells were annotated using epithelial reference populations; endothelial and
212 mural cells were annotated using endothelial, pericyte, and smooth muscle or mural
213 reference populations; lymphoid cells were annotated using T-cell, B-cell, plasma-cell,
214 NK-cell, and related lymphoid reference populations; and myeloid cells were annotated

215 using monocyte, macrophage, dendritic-cell, and mast-cell reference populations
216 where present.

217 For each lineage-specific reference, genes were restricted to those shared between the
218 scRNA-seq reference and the CosMx 6,000-plex panel. Differentially expressed genes
219 defining each reference cell type or state were identified from the scRNA-seq reference,
220 and genes overlapping the CosMx panel were retained. These genes were used to
221 generate pseudo-bulk expression profiles for each reference cell type or cell state. The
222 resulting lineage-specific pseudo-bulk matrices were supplied to InSituType together
223 with the CosMx raw count matrix and negative control count matrix.

224 InSituType was then run independently for each broad CosMx lineage, producing fine
225 cell-type or cell-state predictions within that lineage only. The final fine annotation for
226 each CosMx cell was therefore constrained by its manually refined broad lineage. This
227 prevented, for example, stromal cells from being assigned epithelial or immune labels
228 and ensured that fine labels were selected only from biologically plausible candidates
229 within each compartment.

230

231 *Final CosMx annotation curation*

232 Following lineage-restricted InSituType annotation, predicted fine labels were reviewed
233 within each broad compartment. Annotation quality was assessed using marker-gene
234 expression, spatial distribution, cluster structure, and consistency with the scRNA-seq
235 reference. Where InSituType predictions were inconsistent with marker expression or
236 spatial context, annotations were manually reviewed and, where appropriate, adjusted
237 at the cluster level rather than the individual-cell level.

238 The final CosMx annotation therefore consisted of two linked levels: a refined broad
239 lineage label and a lineage-restricted fine cell-type or cell-state label. The broad lineage
240 label was used for compartment-level analyses and tumour-cell selection, whereas the
241 fine annotation was used to investigate cell-state heterogeneity within epithelial,
242 stromal, endothelial and mural, lymphoid, and myeloid compartments. Where fine-
243 grained subtype resolution was limited by low cell numbers, restricted CosMx gene-
244 panel coverage, or transcriptional similarity between closely related populations,
245 annotations were collapsed to broader biologically interpretable classes; consequently,

246 not all 34 scRNA-seq reference cell types were resolved in the CosMx data, and closely
247 related populations such as T-cell subtypes were grouped as “T cells”.

248

249 *Inference of copy-number alteration signal from CosMx expression data*

250 Large-scale copy-number alteration (CNA)-like signal was inferred from cell-level CosMx
251 spatial transcriptomic profiles using infercnvpy, the Python implementation of the
252 inferCNV approach. Because this analysis infers CNV signal indirectly from transcript
253 abundance, results were interpreted as *putative large-scale CNA signal* rather than
254 direct DNA copy-number calls. infercnvpy estimates CNV-like signal by comparing
255 expression across genes ordered by genomic position to a reference population,
256 followed by genomic smoothing, cell-wise centering, noise filtering and median filtering.
257 Analyses were performed independently for each of the 10 CosMx samples, comprising
258 five biopsy specimens and five matched post-treatment resections from OAC TRG3
259 cases. For each sample, genes from the CosMx 6,000-gene panel were annotated with
260 chromosome and genomic position, restricted to autosomal genes with available
261 coordinates, and ordered by genomic location. Cell annotations in Mid_confidence_fine
262 were used to define malignant and non-malignant compartments. Cells annotated as
263 Lymphoid, Myeloid, Endothelial and Stromal were used as the non-malignant reference
264 population, while cells annotated as Cancer were evaluated for tumour-associated CNV
265 signal.

266 infercnvpy was run using reference_key="Mid_confidence_fine" and non-malignant
267 reference categories as above. A running genomic window of 100 genes was used
268 (window_size=100), with the default step size of 10 genes unless otherwise specified.
269 Sex chromosomes were excluded, retaining autosomal CNV profiles. The resulting
270 smoothed CNV matrix was stored for each sample and visualised as chromosome-
271 ordered heatmaps grouped by cell annotation. The infercnvpy documentation lists
272 window_size=100, step=10, dynamic_threshold=1.5 and exclusion of chrX/chrY as
273 defaults, so this wording is appropriate if you did not override those parameters.

274 For downstream summarisation, a per-cell CNV amplitude score was calculated as the
275 mean absolute CNV signal across all inferred genomic windows:

277

$$\text{CNV amplitude}_i = \frac{1}{W} \sum_{w=1}^W |X_{iw}|$$

276

278 where X_{iw} is the inferred CNV signal for cell i in genomic window w , and W is the total
279 number of inferred windows. This score was used to compare CNV burden across
280 annotated cell types and to visualise the distribution of CNV signal in cancer versus non-
281 malignant populations.

282

283 *Identification and spatial mapping of malignant transcriptional programmes*

284 *Selection of malignant cells from the scRNA-seq reference*

285 Malignant epithelial cells were selected from the harmonised single-cell RNA-seq
286 reference using the consensus cancer-cell annotation. The RPCA-integrated object was
287 used only to define harmonised cell identities and metadata. All transcriptional
288 programme discovery was performed using the uncorrected RNA assay count matrix.

289 To minimise the influence of low-quality or poorly represented donors, only donors with
290 at least 50 malignant epithelial cells were retained. To prevent donors with very large
291 malignant-cell numbers from dominating downstream analyses, a maximum of 500
292 malignant cells per donor was randomly sampled using a fixed random seed. Donor,
293 dataset, sequencing platform, treatment status, and tissue-source metadata were
294 retained for downstream assessment of potential biological and technical associations
295 with inferred programmes.

296 Protein-coding genes were retained based on Ensembl annotations obtained using
297 biomaRt. Mitochondrial genes and ribosomal genes were excluded to reduce technical
298 and housekeeping-driven variation. Raw UMI counts were extracted from the RNA assay
299 and library-size normalised to counts per million (CPM). CPM values were log_{1p}-
300 transformed for variance estimation. Highly variable genes were identified by gene-wise
301 variance across the log_{1p}-transformed CPM matrix, and the top 3,000 genes were
302 retained for NMF. For NMF input, the selected log_{1p}-transformed CPM matrix was
303 transformed back to linear scale using `expm1`, yielding a non-negative CPM-scale gene-
304 by-cell matrix.

305

306 *Consensus non-negative matrix factorisation*

307 Non-negative matrix factorisation was performed using the Brunet multiplicative-update
308 algorithm implemented in the NMF R package. The expression matrix, with genes as rows
309 and cells as columns, was factorised into a gene-by-programme matrix W and a
310 programme-by-cell matrix H . Factorisation was performed for ranks $k = 4$ to $k = 10$. For
311 each rank, 50 random initialisations were performed, with a maximum of 400 iterations
312 per run.

313 For each run, the W matrix was extracted and column-normalised so that gene weights
314 for each programme summed to one. To identify stable consensus
315 programmes, W matrices from all runs at a given rank were concatenated, and pairwise
316 cosine similarity was calculated between programmes. Programmes were clustered
317 using hierarchical clustering on cosine distance, defined as $1 - \text{cosine similarity}$, with
318 average linkage. The dendrogram was cut into k clusters, and consensus programmes
319 were defined by averaging gene weights across programmes within each cluster,
320 followed by column normalisation.

321

322 *Selection of optimal factorisation rank*

323 Programme stability was evaluated across values of k by calculating the mean within-
324 cluster cosine similarity of programmes across independent NMF runs. This metric
325 reflects the reproducibility of inferred transcriptional programmes across random
326 initialisations. Candidate ranks were also assessed for biological interpretability,
327 pathway enrichment, top-weighted marker genes, and distribution of programme usage
328 across donors, datasets, and sequencing platforms.

329 Based on the balance between programme stability, interpretability, and avoidance of
330 donor- or platform-dominated factors, $k = 5$ was selected for downstream analyses.

331

332 *Scoring scRNA-seq malignant cells for consensus programmes using AUCell*

333 To map cNMF-derived tumour transcriptional programmes onto malignant cells from the
334 scRNA-seq reference, a rank-based enrichment strategy was implemented using
335 AUCell. The consensus W matrix containing five tumour programmes was used to define

336 programme-specific gene sets. For each programme, genes were ranked by consensus
337 weight, and the top 50 genes were selected as the initial programme gene set.

338 To reduce redundancy between programmes and improve specificity of programme
339 scoring, gene overlap across the five programme gene sets was quantified. Genes
340 assigned to more than one programme were removed, retaining only genes uniquely
341 associated with a single programme. These refined non-overlapping gene sets were used
342 for AUCell scoring.

343 Raw RNA assay counts from malignant scRNA-seq cells were library-size normalised to
344 CPM. Gene-expression rankings were generated for each cell
345 using `AUCell_buildRankings()`, with block-wise ranking enabled to improve memory
346 efficiency. Programme enrichment was quantified using `AUCell_calcAUC()`, which
347 calculates the area under the curve for each programme gene set within each cell's
348 ranked gene list. The maximum rank considered for AUC calculation was restricted to the
349 top 100 genes per cell to prioritise highly expressed genes and reduce the influence of
350 low-level noise. The resulting AUCell scores were stored as cell-by-programme
351 metadata in the Seurat object.

352 Because AUCell scores are relative to each cell's ranked expression distribution and may
353 vary between datasets, AUC values were z-score normalised within cohort prior to
354 categorical programme assignment. For each cell, the programme with the highest z-
355 scored AUCell value was designated as the candidate dominant programme. To avoid
356 forced assignment of weak or ambiguous programme states, two additional criteria were
357 applied: a minimum z-score of 1.0 for the top programme and a minimum margin of 0.25
358 between the highest and second-highest z-scored programme scores. Cells failing the z-
359 score threshold and margin criterion were labelled ambiguous. Cells satisfying both
360 criteria were assigned a final AUCell-based tumour programme label.

361

362 *Hallmark enrichment of consensus cNMF programmes (fgsea)*

363 Hallmark pathway enrichment was performed directly on the consensus cNMF gene-
364 programme matrix (consensus W), treating each programme as a ranked gene list.
365 Consensus W (genes × programmes) was loaded from the cNMF output and gene
366 identifiers were verified to be HGNC gene symbols matching MSigDB naming. Hallmark

367 gene sets were obtained using msigdb (species = Homo sapiens, category = “H”) and
368 converted into a list of pathways (each pathway containing its member gene symbols).
369 For each cNMF programme, genes were ranked by their consensus W weight in that
370 programme (decreasing order) and used as the statistic vector for enrichment testing.
371 Enrichment testing was performed using fgseaMultilevel (from the fgsea package), which
372 estimates enrichment without requiring a fixed permutation count and is stable for long
373 ranked lists. For each programme, we retained enrichment results with associated NES
374 and Benjamini-Hochberg adjusted P values (FDR).

375

376 *Transcription factor activity analysis of cNMF tumour programmes*

377 Transcription factor activity was inferred for the five malignant transcriptional
378 programmes using DoRothEA regulons and the decoupleR framework. Malignant cells
379 assigned to one of the five cNMF tumour programmes by AUCell were selected from the
380 scRNA-seq reference. Cells labelled as ambiguous were excluded from this analysis.

381 For each programme, RNA expression was aggregated across all malignant cells
382 assigned to that programme using Seurat’s AggregateExpression() function with the RNA
383 assay and log-normalised expression values from the data slot. This produced a gene-
384 by-programme expression matrix representing the average transcriptional profile of each
385 cNMF programme.

386 Transcription factor activities were inferred using run_mlm() from decoupleR with the
387 human DoRothEA regulon database. DoRothEA confidence levels A, B, and C were
388 retained to balance regulon confidence and coverage. The regulon network was
389 restricted to target genes present in the aggregated scRNA-seq expression matrix.

390 Transcription factors with fewer than 10 measured target genes were excluded. For each
391 transcription factor, decoupleR’s multivariate linear model estimated an activity score
392 for each cNMF programme based on the expression of its signed target-gene regulon.

393 To identify transcription factors preferentially active in each tumour programme, a
394 programme-specificity score was calculated for each transcription factor and
395 programme. For a given transcription factor t and programme p , specificity was defined
396 as:

$$397 \quad \textit{Specificity}(t,p) = \textit{Activity}(t,p) - \textit{mean}(\textit{Activity}(t,q))$$

398 where q represents all other cNMF programmes. For each programme, the top 15
399 transcription factors with the highest specificity scores were selected. The union of these
400 programme-specific transcription factors was retained for visualisation.

401 For the heatmap shown in panel f, transcription factor activity scores for the selected
402 transcription factors were extracted across the five cNMF programmes and z-score
403 scaled across programmes for each transcription factor. This row-wise scaling was used
404 to visualise the relative activity pattern of each transcription factor across tumour
405 programmes. Heatmaps were generated using ComplexHeatmap, with cNMF
406 programmes displayed as columns and transcription factors as rows.

407

408 *Selection of representative programme genes*

409 To provide a compact and interpretable summary of gene-level drivers for each
410 programme, representative genes were selected from the consensus W matrix using a
411 combined weight-and-specificity criterion. For each gene g and programme p , a
412 specificity ratio was calculated as:

$$414 \quad \textit{Specificity}(g, p) = \frac{W_{g,p}}{\max_{q \neq p} (W_{g,q}) + \epsilon}$$

413

415 where $W_{g,p}$ is the consensus weight of gene g in programme p , q indexes all other
416 programmes, and ϵ is a small constant to avoid division by zero. Genes were ranked
417 within each programme using the combined score:

$$419 \quad \textit{Score}(g, p) = W_{g,p} \times \textit{Specificity}(g, p)$$

418

420 For each programme, representative genes were selected by prioritising genes with high
421 combined scores, programme-specific weighting, and biological relevance. Where
422 genes were highlighted in the Results section and were present in the W matrix, they
423 were preferentially included, and remaining slots were filled using the highest-ranked
424 genes by the combined weight-specificity score. Four to six representative genes were
425 selected per programme.

426

427 *Summarising programme phenotypes across mechanistic axes*

428 To summarise each tumour programme's biological phenotype, a set of mechanistic
429 axes was defined a priori. These axes included proliferation, interferon response, MHC
430 class I antigen presentation, stress or AP-1 activation, Notch-associated plasticity,
431 polarity or junctional organisation, secretory differentiation, and regenerative repair.
432 Each axis was represented by a compact gene set selected based on pathway biology,
433 marker coherence, and relevance to epithelial tumour-cell states.
434 Axis scores were calculated per cell using Seurat's `AddModuleScore()`, with each
435 mechanistic gene set scored against matched control features. Axis scores were
436 summarised across cells assigned to each tumour programme using the median. For
437 comparability across programmes, median axis scores were scaled to the unit interval
438 from 0 to 1 across programmes for each axis:

$$440 \quad x' = \frac{x - \min(x)}{\max(x) - \min(x) + \epsilon}$$

439

441 where x is the median axis score and ϵ is a small constant to avoid division by zero. Radar
442 plots were generated using the scaled axis values, with axes and scaling held constant
443 across all programmes to enable direct comparison of phenotypic profiles.

444

445 *Projection of tumour transcriptional programmes into CosMx spatial data*

446 *CosMx malignant-cell processing for programme projection*

447 CosMx spatial transcriptomics data were subset to include high-confidence malignant
448 epithelial cells based on the final consensus and manually refined annotations. Raw UMI
449 count matrices were extracted from the RNA assay with genes as rows and cells as
450 columns. To ensure compatibility with the scRNA-seq-derived cNMF programmes,
451 CosMx counts were normalised to CPM without log-transformation, preserving non-
452 negativity for downstream NNLS projection.

453 Only genes shared between the CosMx panel and the consensus cNMF W matrix were
454 retained. The consensus programme matrix was subset to this shared gene set, and
455 programme columns were re-normalised after subsetting to account for differences in
456 gene coverage between whole-transcriptome scRNA-seq and targeted CosMx profiling.

457

458 *Projection of cNMF programmes onto CosMx data using non-negative least squares*

459 Consensus cNMF programmes derived from scRNA-seq malignant cells were projected
460 onto individual CosMx malignant cells using non-negative least squares regression.
461 NNLS was used rather than retraining NMF on the spatial data, allowing the scRNA-seq-
462 derived tumour programmes to be transferred into spatial coordinates while avoiding the
463 introduction of additional latent structure from the lower-complexity CosMx panel.

464 For each CosMx cell, its CPM-normalised expression vector x was modelled as a non-
465 negative linear combination of the consensus programmes:

$$466 \quad x \approx Wh$$

467 where W is the shared-gene consensus programme matrix and h is the vector of non-
468 negative programme usage coefficients for that cell. NNLS regression was performed
469 independently for each cell using the nnls R package. The resulting coefficients were
470 retained as continuous programme-usage scores. Where relative programme
471 composition was required, coefficients were normalised per cell to sum to one.

472 Unlike simple correlation or matrix multiplication, NNLS constrains programme
473 contributions to be non-negative and additive. This makes it suitable for estimating the
474 contribution of multiple transcriptional programmes within each CosMx cell while
475 preserving interpretability of programme usage scores.

476

477 *AUCell scoring of tumour programmes in CosMx data*

478 As a complementary approach to NNLS-based programme projection, CosMx malignant
479 cells were scored using AUCell. The same refined, non-overlapping programme gene
480 sets used for scRNA-seq scoring were applied to the CosMx data, restricted to genes
481 present in the CosMx panel.

482 AUCell rankings were generated for each CosMx cell, and programme enrichment was
483 quantified using `AUCell_calcAUC()` with the same maximum-rank parameter used for
484 scRNA-seq scoring. AUCell scores were z-score normalised within each sample to
485 account for sample-specific variation in transcript detection, segmentation, and local
486 RNA density. Dominant programme labels were assigned using the same z-score and
487 margin criteria applied to the scRNA-seq data.

488 AUCell was used as a rank-based measure of programme identity, whereas NNLS was
489 used to estimate continuous programme usage. Using both approaches enabled
490 categorical assignment of dominant tumour-cell state together with quantitative
491 assessment of programme composition.

492

493 *Spatial visualisation of tumour transcriptional programmes*

494 Programme usage scores, dominant programme assignments, assignment confidence,
495 and ambiguity status were visualised in tissue coordinates across CosMx sections.
496 Spatial maps were generated using cell centroid coordinates and overlaid with tumour
497 programme labels or continuous programme scores. These visualisations were used to
498 assess spatial organisation of malignant transcriptional states, intra-tumoural
499 heterogeneity, co-localisation of programmes, and boundary regions between
500 transcriptionally distinct tumour compartments.

501 Where relevant, spatial programme distributions were compared with H&E morphology,
502 manually refined malignant annotations, and local tissue architecture to support
503 biological interpretation of tumour-cell states in situ.

504

505 *Spatial autocorrelation analysis using Moran's I*

506 Spatial autocorrelation of malignant cNMF programme activity was assessed in CosMx
507 spatial transcriptomics data using global Moran's I. Cancer cells were identified using
508 the final refined cell-type annotation and were defined as cells labelled "Cancer". Cell
509 centroid coordinates were extracted from the CosMx metadata and converted from
510 pixels to micrometres using a scaling factor of 0.12 μm per pixel. Only cells from retained
511 fields of view were included in the analysis.

512 Analyses were performed on continuous cNMF programme scores rather than
513 thresholded programme labels. This preserved the full range of programme activity and
514 allowed Moran's I to test whether neighbouring cancer cells had similar levels of each
515 transcriptional programme.

516 For each analysis group, cancer-cell centroid coordinates were used to construct a
517 spatial neighbour graph. Each cancer cell was connected to its eight nearest
518 neighbouring cancer cells using a k-nearest-neighbour approach. The neighbour graph

519 was converted to a row-standardised spatial weights matrix. Global Moran's I was then
520 calculated separately for each continuous cNMF programme score using the spdep R
521 package. Positive Moran's I values were interpreted as evidence that neighbouring
522 cancer cells had similar programme activity, consistent with spatial clustering of that
523 malignant transcriptional state. Values close to zero indicated limited spatial
524 autocorrelation.

525 Statistical significance was assessed using both the analytical Moran's I test and a
526 Monte Carlo permutation-based Moran's I test. Analytical tests were performed
527 using `spdep::moran.test()`. For the Monte Carlo test, `spdep::moran.mc()` was used with
528 1,000 permutations. In each permutation, cNMF programme scores were randomly
529 reassigned across the fixed cancer-cell spatial graph, preserving the cell coordinates
530 and neighbour relationships while disrupting the association between spatial position
531 and programme activity. The observed Moran's I statistic was compared with this
532 permutation-derived null distribution to obtain an empirical P value. P values were
533 adjusted across the five cNMF programmes using the Benjamini-Hochberg false
534 discovery rate procedure.

535

536 *Comparison of cNMF tumour programme activity between paired biopsies and* 537 *resections*

538 To compare malignant transcriptional programme activity between diagnostic biopsies
539 and matched resections, CosMx objects from five paired OAC cases were analysed.
540 High-confidence malignant epithelial cells were used for the comparison. For each cell,
541 cNMF programme activity scores were extracted from the metadata and converted to
542 long format, producing a cell-by-programme table containing patient, condition, sample
543 identifier, programme, and programme score.

544 For visualisation of the cell-level distribution of programme activity, programme scores
545 were plotted by condition using violin plots with overlaid boxplots. These plots show the
546 distribution of single-cell cNMF programme scores across biopsy and resection samples
547 for each programme. Mean differences between resection and biopsy scores were
548 calculated for each programme and displayed as Δ values, where positive values
549 indicate higher scores in resection samples.

550 To account for the paired patient structure, per-patient summaries were calculated for
551 each condition and programme. For each patient, condition, and cNMF programme, the
552 median programme score across malignant cells was calculated. These paired patient-
553 level medians were visualised using connected line plots, with each line representing
554 one patient and showing the change from biopsy to matched resection. Paired Wilcoxon
555 signed-rank tests were used to compare biopsy and resection median programme
556 scores for each cNMF programme. P values were adjusted across the five programmes
557 using the Benjamini-Hochberg false discovery rate procedure.

558 As an additional cell-level analysis accounting for repeated sampling within patients,
559 linear mixed-effects models were fitted separately for each cNMF programme.
560 Programme score was modelled as a function of condition, with biopsy as the reference
561 level and patient included as a random intercept:

562

$$564 \quad \text{Score}_{ij} = \beta_0 + \beta_1 \text{Condition}_{ij} + u_{\text{patient}} + \epsilon_{ij}$$

563

565 where β_1 estimates the change in programme score in resection relative to biopsy.
566 Models were fitted using the lme4 R package. For each programme, the condition effect
567 was reported as the estimated resection-minus-biopsy change with an approximate 95%
568 confidence interval calculated as estimate \pm 1.96 \times standard error. Statistical
569 significance was assessed by comparing the full model with a null model lacking the
570 condition term using a likelihood ratio test. P values were adjusted across programmes
571 using the Benjamini-Hochberg method.

572 The violin plots were used to display the single-cell distribution of cNMF programme
573 activity, the paired line plots were used to show patient-level biopsy–resection changes,
574 and the mixed-effects model was used to estimate the overall condition effect while
575 accounting for inter-patient variation.

576

577 *Spatial niche identification and cancer-centred neighbourhood analysis*

578 Spatial niche analysis was performed using the final annotated CosMx Seurat objects.
579 For the analyses shown in panels c–f, resection samples were used. Cell centroid
580 coordinates were extracted from the CosMx metadata using the global x and y pixel

581 coordinates and converted to micrometres using a scaling factor of 0.12 μm per pixel.
582 Cell identities were taken from the final refined annotation.

583

584 *Unsupervised spatial niche identification*

585 To identify recurrent multicellular neighbourhoods within individual tissue sections,
586 unsupervised niche analysis was performed using Seurat's BuildNicheAssay() function.
587 For each selected CosMx section, a niche assay was constructed using final refined cell-
588 type annotations as the categorical input. For each cell, the local cellular neighbourhood
589 was defined using its 30 nearest spatial neighbours. The composition of these local
590 neighbourhoods was encoded as a cell-type count matrix and clustered into discrete
591 spatial niches.

592

593 Spatial niche labels were mapped back onto the tissue coordinates and visualised using
594 ImageDimPlot(). To interpret the cellular composition of each niche, the niche count
595 matrix was extracted and converted to neighbourhood cell-type proportions. For each
596 niche, the mean local cell-type composition was compared with the background cell-
597 type frequency across the section. Cell-type enrichment within each niche was
598 quantified using Fisher's exact tests on aggregated neighbourhood cell-type counts. P
599 values were adjusted using the Benjamini-Hochberg method, and cell types with FDR <
600 0.05 and log₂ fold enrichment greater than log₂(1.5) were considered enriched. Enriched
601 cell types were used to annotate the dominant cellular constituents of each niche.

602

603 *Selection of spatial niche number*

604 The number of spatial niche clusters was selected using a data-driven assessment of
605 clustering performance across candidate values of k . For each CosMx section, spatial
606 niche features were first generated using Seurat's BuildNicheAssay() function with final
607 refined cell-type annotations as input. Local neighbourhoods were defined using the 30
608 nearest neighbours of each cell. The resulting niche assay encoded, for each cell, the
609 composition of its local cellular neighbourhood.

610 To evaluate the optimal number of niche clusters, candidate values from $k = 2$ to $k =$
611 10 were tested. For each candidate k , k-means clustering was applied to the niche

612 composition matrix using 50 random starts. Prior to clustering, the niche matrix was
613 filtered to remove cells with zero neighbourhood counts and was scaled across features.
614 Clustering performance was assessed using total within-cluster sum of squares,
615 between-cluster sum of squares, the ratio of between-cluster sum of squares to total
616 sum of squares, average silhouette width, and minimum and maximum cluster size.
617 To assess clustering robustness, repeated k-means runs were performed for each
618 candidate k , and pairwise adjusted Rand indices were calculated between replicate
619 cluster assignments. The mean adjusted Rand index was used as a stability metric.
620 Candidate niche numbers were ranked by average silhouette width, clustering stability,
621 and parsimony, with a small penalty applied to larger values of k . The selected niche
622 number was then used to rebuild the final niche assay using BuildNicheAssay(), and the
623 resulting niche labels were mapped back to spatial coordinates for visualisation.
624 Elbow plots of total within-cluster sum of squares and line plots of average silhouette
625 width and clustering stability were inspected to support the final selection of niche
626 number. Final niche numbers were chosen to balance statistical separation, clustering
627 stability, cluster size, and biological interpretability of the resulting spatial patterns.

628

629 Cancer-centred radius-based neighbourhood composition

630 To quantify the cellular composition surrounding malignant epithelial cells, a cancer-
631 centred neighbourhood analysis was performed across the resection samples. Cancer
632 cells were defined as cells labelled “Cancer” in the final refined annotation. For each
633 sample, Euclidean distances were calculated from each cancer-cell centroid to
634 neighbouring cells using the global micrometre coordinates.

635 For each cancer cell, fixed-radius neighbourhoods were defined at radii of 10, 25, 50, 75,
636 100, and 200 μm using dbSCAN::frNN(). The central cancer cell itself was excluded from
637 its own neighbourhood. For each radius, the proportion of neighbouring cells belonging
638 to each fibroblast or immune subtype was calculated as:

$$640 \quad \%_{celltype} = \frac{n_{celltype \text{ within radius}}}{n_{all \text{ neighbours within radius}}} \times 100$$

639

641 where the denominator included all neighbouring cells within the radius, excluding the
642 index cancer cell. This generated a per-cancer-cell neighbourhood composition profile
643 for each radius.

644 For each sample, percentages were averaged across all cancer cells to obtain a sample-
645 level mean percentage for each cell type and radius. Sample-level values were then
646 averaged across resection samples to generate curves.

647 Fibroblast subtypes included quiescent fibroblast 1, quiescent fibroblast 2, universal
648 fibroblast, transitional fibroblast, stress responsive CAF, MyoCAF, and desmoplastic
649 CAF. Immune subtypes included T cells, Tregs, NK cells, B cells, plasma cells, M1
650 macrophages, M2 macrophages, monocytes, dendritic cells, and granulocytes. Curves
651 were plotted using ggplot2, with radius in micrometres on the x-axis and the mean
652 percentage among neighbours on the y-axis.

653

654 *Distance-to-cancer analysis of non-malignant cell types*

655 To assess the spatial proximity of stromal and immune populations to malignant
656 epithelial cells, nearest-neighbour distances to cancer cells were calculated for all non-
657 cancer cell types in resection samples. Cell centroid coordinates were extracted from
658 the global CosMx coordinate metadata and converted from pixels to micrometres using
659 a scaling factor of 0.12 μm per pixel.

660 For each resection sample, the Euclidean distance from every cell to its nearest cancer
661 cell was calculated using the get.knnx() function from the FNN R package. Distances
662 were calculated independently within each sample to avoid measuring distances across
663 separate tissue sections. For each non-cancer cell type, empirical cumulative
664 distribution functions were generated from the distribution of nearest-cancer distances
665 within each sample. ECDF values were evaluated over a regular distance grid from 0 to
666 500 μm in 5 μm increments.

667 To summarise distance distributions across samples, ECDF values were averaged
668 across resection samples for each cell type and distance. The resulting curves show, for
669 each distance threshold, the mean fraction of cells of a given type located within that
670 distance of the nearest cancer cell. MyoCAFs and M2 macrophages were highlighted,
671 while other non-cancer cell types were shown in grey. This analysis was used to compare

672 the relative proximity of MyoCAFs, M2 macrophages, and other stromal or immune cell
673 types to malignant epithelial regions.

674

675 *Tri-cell cancer–fibroblast–immune niche analysis*

676 To quantify whether cancer cells were embedded in multicellular niches containing both
677 fibroblast and immune populations, a tri-cell neighbourhood analysis was performed.
678 Cancer cells were used as anchor cells. For each cancer cell, fixed-radius
679 neighbourhoods were queried to determine whether at least one fibroblast subtype and
680 at least one immune-cell subtype were present within the specified radius.

681 Fibroblast subtypes included quiescent fibroblast 1, quiescent fibroblast 2, universal
682 fibroblast, transitional fibroblast, stress responsive CAF, MyoCAF, and desmoplastic
683 CAF. Immune subtypes included T cells, Tregs, NK cells, B cells, plasma cells, M1
684 macrophages, M2 macrophages, monocytes, dendritic cells, and granulocytes. Cancer
685 cells were also stratified by cNMF tumour programme where relevant.

686 For each sample, radius-based neighbour searches were performed using
687 `dbscan::frNN()` on cell centroid coordinates in micrometres. For every cancer cell, binary
688 indicators were recorded for whether a given fibroblast subtype was present within the
689 radius and whether a given immune subtype was present within the same radius. A tri-
690 cell niche was defined as a cancer cell for which both conditions were true:

691

$$692 \quad \text{TriCellNiche} = \text{hasFibroblastSubtype} \cap \text{hasImmuneSubtype}$$

692

694 For each sample, patient, condition, cancer programme, fibroblast subtype, immune
695 subtype, and radius, the percentage of cancer cells in a tri-cell niche was calculated as:

696

$$698 \quad \%TriCellNiche = \frac{n_{\text{cancer cells with both fibroblast and immune neighbour}}}{n_{\text{cancer cells}}} \times 100$$

697

699 For the analysis shown in panel h, the model focused on MyoCAF-containing tri-cell
700 niches. The outcome was the percentage of cancer cells with both a MyoCAF and a given
701 immune-cell subtype nearby. To determine whether M2 macrophages were
702 preferentially associated with MyoCAF-containing cancer niches after accounting for

703 differences in cell-type abundance, a linear mixed-effects model was fitted using lme4.
704 The model included immune-cell subtype, fibroblast subtype, cancer programme,
705 immune-cell abundance, fibroblast abundance, and cancer-programme abundance as
706 fixed effects, with patient included as a random intercept:

```
707  
709 %TriCellNiche  
710     ~ ImmuneSubtype + FibroblastSubtype + CancerProgram  
711     + scale(%Immune) + scale(%Fibroblast) + scale(%CancerProgram)  
712     + (1 | Patient)
```

708
713 M2 macrophage was used as the reference immune subtype. Sample-level immune,
714 fibroblast, and cancer-programme abundances were calculated as the percentage of all
715 cells in each sample assigned to the corresponding class and were included as scaled
716 covariates. Estimated marginal means were calculated using emmeans to obtain
717 abundance-adjusted tri-cell niche frequencies for each immune subtype, allowing
718 comparison of M2 macrophages with other immune populations while accounting for
719 sample-level cell-type abundance and patient structure.

720

721 *CellPhoneDB ligand–receptor analysis of the cancer–MyoCAF–M2 macrophage niche*

722 Cell–cell communication analysis was performed on the integrated single-cell RNA-seq
723 reference using CellPhoneDB. Cancer cells were stratified by their dominant cNMF
724 tumour programme, generating five malignant sender/receiver groups corresponding to
725 the Immune-primed, Proliferative, Invasive, Stress repair, and Stress adapted
726 programmes. Stromal and immune populations of interest were defined from the fine
727 cell-type annotations.

728 CellPhoneDB was run using the single-cell expression matrix and corresponding cell-
729 group metadata. The resulting ligand–receptor interaction table was exported in long
730 format, retaining source cell type, target cell type, ligand gene, receptor gene, interacting
731 pair, CellPhoneDB classification, significant mean, and interaction score. Downstream
732 analysis focused on interactions involving the tri-cell niche of interest: cNMF-defined
733 cancer programmes, MyoCAFs, and M2 macrophages.

734 Interactions were filtered to retain directed edges between cancer programmes and
735 MyoCAFs, cancer programmes and M2 macrophages, and reciprocal MyoCAF–M2
736 macrophage interactions. Self-interactions within the same stromal or immune
737 population were excluded..

738 To aid biological interpretation, ligand–receptor interactions were collapsed into
739 manually curated pathway categories using the CellPhoneDB classification field and
740 ligand/receptor gene identities. Interactions were assigned to the following pathway
741 classes: WNT/RSPO, BMP, TGF-beta, FGF, NOTCH, Myeloid-conditioning, Immune
742 evasion, HGF/MET, EGFR/ERBB, and ECM/integrin. Interactions that did not match these
743 predefined categories were retained as “Other” where appropriate.

744 For global visualisation of the niche communication network, directed chord diagrams
745 were generated using circlize. Cell sectors represented cNMF cancer programmes,
746 MyoCAFs, and M2 macrophages. Links represented directed ligand–receptor
747 interactions between source and target populations and were coloured by pathway
748 class. Chord diagrams were generated either using the number of interactions per cell-
749 pair/pathway or the summed CellPhoneDB interaction score.

750 To summarise pathway-level communication patterns, interactions were aggregated by
751 directed cell pair and pathway. For each source–target pair, the number of interactions
752 and the summed CellPhoneDB interaction score were calculated for each pathway.
753 Summed interaction scores were log_{1p}-transformed for heatmap visualisation.
754 Heatmaps were generated using pheatmap, with rows representing directed cell pairs
755 and columns representing pathway classes. Directed cell-pair ordering was fixed to
756 show cancer-to-MyoCAF, cancer-to-M2 macrophage, MyoCAF-to-cancer, MyoCAF-to-
757 M2 macrophage, M2 macrophage-to-cancer, and M2 macrophage-to-MyoCAF
758 interactions.

759 To compare the overall number of interactions sent or received by each tumour
760 programme, CellPhoneDB interactions were summarised by source and target group.
761 For each cNMF cancer programme, the number of outgoing interactions to MyoCAFs and
762 M2 macrophages was calculated, as was the number of incoming interactions from
763 MyoCAFs and M2 macrophages. These counts were visualised as column-scaled
764 heatmaps to highlight relative sending and receiving patterns across tumour
765 programmes.

766

767 *Curated ligand–receptor interaction plots*

768 Curated ligand–receptor dot plots were generated to visualise selected CellPhoneDB
769 interactions within the cancer–MyoCAF–M2 macrophage niche. For these plots, each
770 point represents a directed ligand–receptor interaction between a source and target cell
771 population. Point size represents the CellPhoneDB interaction score, and point colour
772 represents the CellPhoneDB significant mean.

773 The CellPhoneDB significant mean is an expression-based summary of interaction
774 strength for statistically significant ligand–receptor pairs. It reflects the mean expression
775 of the ligand in the source cell group and the receptor in the target cell group, with multi-
776 subunit complexes represented by the limiting subunit. In the CellPhoneDB significant-
777 means output, values are retained for interactions passing the permutation-based
778 significance threshold, whereas non-significant interactions are not assigned a positive
779 significant-mean value. Higher significant-mean values therefore indicate stronger
780 expression support for a statistically significant interaction in a given source–target
781 direction, but should be interpreted as a relative communication score rather than a
782 direct biochemical measure of ligand–receptor binding.

783 Interactions were selected to highlight cancer-programme-specific communication with
784 MyoCAFs and M2 macrophages. For each ligand–receptor pair, interaction strength was
785 compared across the five cNMF cancer programmes. Interactions were retained if they
786 were unique to a single cancer programme or if their interaction strength in one cancer
787 programme was at least 1.5-fold higher than in the other cancer programmes. This
788 selection strategy was used to identify ligand–receptor interactions preferentially
789 associated with individual malignant transcriptional states.

790 MyoCAF–M2 macrophage interactions were summarised at the pathway level. Within
791 each curated pathway class, interactions were ranked by CellPhoneDB significant mean,
792 and up to the top 12 interactions per pathway were retained for visualisation. Additional
793 biologically relevant interactions were manually retained where appropriate to aid
794 interpretation of the MyoCAF–M2 macrophage niche. Dot plots were faceted by pathway
795 and sender–receiver direction.

796

797 *Spatial-context differential expression of cancer cells in the MyoCAF–M2 macrophage*
798 *niche*

799 To identify cancer-cell transcriptional changes associated with localisation in a
800 MyoCAF–M2 macrophage niche, spatial-context differential expression analysis was
801 performed on CosMx resection samples. Resection samples were analysed
802 independently and stored as sample-specific Seurat objects. Final refined cell-type
803 annotations and cNMF cancer-programme annotations were used as input. Cancer cells
804 were defined as cells annotated as one of the five malignant cNMF programmes:
805 Immune-primed, Proliferative, Invasive, Stress repair, or Stress adapted. Cells
806 annotated as MyoCAF and M2 macrophage were used to define the niche of interest.
807 Cell centroid coordinates were extracted from the CosMx metadata using global x and y
808 pixel coordinates. Distances were converted to micrometres using a pixel size of 0.12µm.
809 For each sample, radius-based neighbourhoods were constructed using `dbscan::frNN()`.
810 For each cell, all neighbouring cells within the specified radius were identified, excluding
811 the index cell itself. For cancer cells, the number of neighbouring MyoCAFs and M2
812 macrophages within the radius was counted.

813 Each cancer cell was assigned to one of four spatial-context categories:

814

$$816 \quad \text{MyoCAF_M2_niche} = n_{\text{MyoCAF}} > 0 \cap n_{\text{M2 macrophage}} > 0$$

$$817 \quad \text{MyoCAF_only} = n_{\text{MyoCAF}} > 0 \cap n_{\text{M2 macrophage}} = 0$$

$$818 \quad \text{M2_only} = n_{\text{MyoCAF}} = 0 \cap n_{\text{M2 macrophage}} > 0$$

$$819 \quad \text{Neither} = n_{\text{MyoCAF}} = 0 \cap n_{\text{M2 macrophage}} = 0$$

815

820 The primary contrast for differential expression was cancer cells in the
821 “MyoCAF_M2_niche” compared with cancer cells in the “Neither” context. This contrast
822 was performed separately within each cNMF cancer programme.

823 For each cancer programme and spatial context, raw RNA counts were aggregated into
824 sample-level pseudobulk profiles. Pseudobulk counts were generated by summing raw
825 counts across cancer cells from the same sample, cancer programme, and spatial-
826 context category. Contexts containing fewer than 10 cells in a given sample were
827 excluded. Only samples with paired pseudobulk profiles for both “MyoCAF_M2_niche”

828 and “Neither” contexts were retained for the corresponding programme-level
829 comparison. Programmes with fewer than three paired samples were not tested.
830 Differential expression was performed using edgeR. Genes were initially filtered to retain
831 genes with a total count of at least 10 and expression in at least two pseudobulk samples,
832 followed by filterByExpr(). Library-size normalisation was performed using trimmed
833 mean of M-values normalisation with calcNormFactors(). For each cancer programme,
834 a quasi-likelihood negative binomial generalized linear model was fitted with sample
835 identity and spatial context as covariates:

836

838
$$\text{Expression} \sim \text{sample} + \text{spatial context}$$

837

839 The spatial-context coefficient estimated the log₂ fold change for MyoCAF_M2_niche
840 versus Neither while accounting for paired sample structure. Dispersion was estimated
841 using robust estimation, and differential expression was assessed using glmQLFit() and
842 glmQLFTest(). P values were adjusted for multiple testing using the Benjamini-Hochberg
843 false discovery rate procedure. Genes with FDR < 0.1 and absolute log₂ fold change ≥
844 0.25 were considered significant for exploratory interpretation.

845

846 *Niche-radius sensitivity analysis*

847 To assess the effect of neighbourhood radius on niche-associated differential
848 expression, the spatial-context assignment and pseudobulk differential expression
849 workflow were repeated across a series of candidate niche radii (15, 20, 25, 30, 35, 40,
850 45, 50, 55, 60µM). For each radius, cancer cells were reassigned to
851 “MyoCAF_M2_niche”, “MyoCAF_only”, “M2_only”, or “Neither” based on the presence
852 of MyoCAFs and M2 macrophages within that distance. Programme-specific differential
853 expression was then repeated for the “MyoCAF_M2_niche” versus “Neither” contrast.
854 For each radius and cancer programme, the number of significant genes was counted
855 using the threshold FDR < 0.1 and absolute log₂ fold change ≥ 0.25. These counts were
856 plotted against niche radius to evaluate the stability of the transcriptional signal across
857 neighbourhood definitions. The main downstream visualisations used the 25 µm niche
858 definition.

859

860 *Gene-category summarisation and heatmap visualisation*

861 To summarise biological patterns in the spatial-context differential expression results,
862 genes were grouped into manually curated categories. The primary categories shown
863 were epithelial/glandular genes and stress/inflammatory genes. For each cancer
864 programme and gene category, the number of significant genes was calculated using
865 $FDR < 0.1$ and absolute \log_2 fold change ≥ 0.25 . The mean \log_2 fold change among
866 significant genes in each category was also calculated. These values were visualised
867 using a dot plot, where dot size represents the number of significant genes and colour
868 represents the mean \log_2 fold change among significant genes.

869 For heatmap visualisation, selected epithelial/glandular and stress/inflammatory genes
870 were extracted from the differential expression results. Genes were retained for plotting
871 if they were significant in at least one cancer programme. Heatmap values represent the
872 edgeR \log_2 fold change for “MyoCAF_M2_niche” versus “Neither” within each cancer
873 programme. Positive values indicate higher expression in cancer cells located in the
874 MyoCAF–M2 macrophage niche, whereas negative values indicate higher expression in
875 cancer cells lacking nearby MyoCAFs and M2 macrophages. Values were capped for
876 colour-scale visualisation. Significance symbols indicate genes passing the \log_2 fold-
877 change threshold of ≥ 0.25 together with FDR thresholds of < 0.1 , < 0.01 , or < 0.001 .